Novartis announces expiration of Tourmaline Bio tender offer
arcticnovartis
Tue, 10/28/2025 – 07:28
Read more about Novartis announces expiration of Tourmaline Bio tender offer
Basel, October 28 2025 – Novartis tod…
Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
arcticnovartis
Tue, 10/28/2025 – 07:02
Read more about Nov…
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
arcticnovartis
Tue, 10/28/2025 – 07:02
Read more about Novartis delivers solid sales and core operating income growth wi…
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
arcticnovartis
Tue, 10/28/2025 – 07:02
Read more about Novartis delivers solid sales and core operating income growth wi…
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:04
Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis
Sun, 10/26/2025 – 18:03
Read more about Novartis agrees to acquire Avidity Biosciences, an innovat…
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis
Sat, 10/25/2025 – 17:04
Read more about Novartis showcases significant immunology advancements in ACR congress with …
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis
Sat, 10/25/2025 – 17:04
Read more about Novartis showcases significant immunology advancements in ACR congress with …
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
arcticnovartis
Wed, 10/22/2025 – 07:19
Read more about Novartis Cosentyx® meets primary and all secondary endpoints in Ph…
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
arcticnovartis
Wed, 10/22/2025 – 07:04
Read more about Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offe…
